Understand the source comparison
Peptides Help with Concussion Recovery: Treatment Comparison
Before comparing efficacy, understand that peptide interventions are adjunctive—they enhance endogenous repair, they don't replace rest, cognitive rehabilitation, or medical monitoring. Cerebrolysin BDNF/NGF receptor activation; reduces excitotoxicity Phase II
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before comparing efficacy, understand that peptide interventions are adjunctive—they enhance endogenous repair, they don't replace rest, cognitive rehabilitation, or medical monitoring.
- Cerebrolysin
- BDNF/NGF receptor activation; reduces excitotoxicity
- Phase II RCTs in mild-moderate TBI
- 10–21 days (daily injections)
- Requires subcutaneous or IV administration; not orally bioavailable
- Strongest clinical evidence for symptom resolution in subacute phase—most practical for structured recovery protocols
- Dihexa
- HGF/c-Met signaling; synaptogenesis
- Preclinical models only; no human TBI trials
- Experimental (7–14 days studied in rodent models)
- No published human safety data in TBI populations
- Promising mechanistically but lacks human validation—research-use only until Phase I trials complete
- P21
- STAT3 activation; neurogenesis support
- Animal models; anecdotal human use
- 14–28 days
- Blood-brain barrier penetration varies by formulation
- Directly targets hippocampal repair—best for memory/cognitive symptoms but untested in controlled human TBI trials
- Thymalin
- Peripheral immune modulation; reduces systemic IL-6
- Military TBI cohorts (non-RCT observational data)
- 5–10 days
- Indirect CNS effect—works through systemic inflammation reduction, not direct neuroprotection
- Useful as part of multi-modal approach but insufficient as standalone intervention for concussion symptoms